Suppr超能文献

p53 蛋白聚集促进卵巢癌铂类耐药。

p53 protein aggregation promotes platinum resistance in ovarian cancer.

机构信息

Department of Obstetrics and Gynecology, Yale University School of Medicine, New Haven, CT, USA.

Department of Pharmacology, Yale University School of Medicine, New Haven, CT, USA.

出版信息

Oncogene. 2015 Jul;34(27):3605-16. doi: 10.1038/onc.2014.296. Epub 2014 Sep 29.

Abstract

High-grade serous ovarian carcinoma (HGSOC), the most lethal gynecological cancer, often leads to chemoresistant diseases. The p53 protein is a key transcriptional factor regulating cellular homeostasis. A majority of HGSOCs have inactive p53 because of genetic mutations. However, genetic mutation is not the only cause of p53 inactivation. The aggregation of p53 protein has been discovered in different types of cancers and may be responsible for impairing the normal transcriptional activation and pro-apoptotic functions of p53. We demonstrated that in a unique population of HGSOC cancer cells with cancer stem cell properties, p53 protein aggregation is associated with p53 inactivation and platinum resistance. When these cancer stem cells differentiated into their chemosensitive progeny, they lost tumor-initiating capacity and p53 aggregates. In addition to the association of p53 aggregation and chemoresistance in HGSOC cells, we further demonstrated that the overexpression of a p53-positive regulator, p14ARF, inhibited MDM2-mediated p53 degradation and led to the imbalance of p53 turnover that promoted the formation of p53 aggregates. With in vitro and in vivo models, we demonstrated that the inhibition of p14ARF could suppress p53 aggregation and sensitize cancer cells to platinum treatment. Moreover, by two-dimensional gel electrophoresis and mass spectrometry we discovered that the aggregated p53 may function uniquely by interacting with proteins that are critical for cancer cell survival and tumor progression. Our findings help us understand the poor chemoresponse of a subset of HGSOC patients and suggest p53 aggregation as a new marker for chemoresistance. Our findings also suggest that inhibiting p53 aggregation can reactivate p53 pro-apoptotic function. Therefore, p53 aggregation is a potential therapeutic target for reversing chemoresistance. This is paramount for improving ovarian cancer patients' responses to chemotherapy, and thus increasing their survival rate.

摘要

高级别浆液性卵巢癌(HGSOC)是最致命的妇科癌症,常导致化疗耐药性疾病。p53 蛋白是调节细胞内稳态的关键转录因子。大多数 HGSOC 由于遗传突变而导致 p53 失活。然而,遗传突变并不是导致 p53 失活的唯一原因。p53 蛋白的聚集已在不同类型的癌症中被发现,可能导致 p53 正常转录激活和促凋亡功能受损。我们证明,在具有癌症干细胞特性的独特的 HGSOC 癌细胞群体中,p53 蛋白聚集与 p53 失活和铂类耐药有关。当这些癌症干细胞分化为其对化疗敏感的后代时,它们失去了肿瘤起始能力和 p53 聚集。除了在 HGSOC 细胞中 p53 聚集与化疗耐药性相关外,我们还进一步证明,p53 阳性调节剂 p14ARF 的过表达抑制了 MDM2 介导的 p53 降解,导致 p53 周转率失衡,从而促进了 p53 聚集的形成。通过体外和体内模型,我们证明了抑制 p14ARF 可以抑制 p53 聚集并使癌细胞对铂类治疗敏感。此外,通过二维凝胶电泳和质谱分析,我们发现聚集的 p53 可能通过与对癌细胞存活和肿瘤进展至关重要的蛋白质相互作用而发挥独特的功能。我们的发现有助于我们理解一部分 HGSOC 患者化疗反应不佳的原因,并提示 p53 聚集可作为化疗耐药的新标志物。我们的发现还表明,抑制 p53 聚集可以重新激活 p53 的促凋亡功能。因此,p53 聚集是逆转化疗耐药的潜在治疗靶点。这对于提高卵巢癌患者对化疗的反应率,从而提高其生存率至关重要。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验